Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: Disinfectant Effectiveness Test Method – V 2.0

Posted on By

Analytical Method Development: Disinfectant Effectiveness Test Method – V 2.0

Standard Operating Procedure for Disinfectant Effectiveness Testing in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/130/2025
Supersedes SOP/AMD/130/2022
Page No. Page 1 of 14
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP describes a validated procedure for testing the effectiveness of disinfectants used in pharmaceutical cleanrooms and laboratory environments against standard microbial strains on various surfaces and conditions, as per GMP and USP guidelines.

2. Scope

This procedure applies to the Analytical Method Development and Microbiology departments responsible for qualifying new disinfectants and verifying ongoing effectiveness of routine disinfectants used in production and QC areas.

3. Responsibilities

  • Microbiologist: Prepares cultures, executes the test, and analyzes microbial reduction.
  • Analytical Chemist: Prepares disinfectant dilutions and supports documentation.
  • QA Officer: Reviews records and ensures alignment with regulatory standards.
  • Head – AMD: Approves disinfectant qualification protocols and interprets results.
See also  Analytical Method Development: SOP for Surface Area Determination (BET Method) - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring the scientific validity and regulatory compliance of all disinfectant testing performed in the laboratory.

5. Procedure

5.1 Selection of Disinfectants and Organisms

  1. Select commonly used disinfectants:
    • 70% Isopropyl Alcohol (IPA)
    • 0.5% Sodium Hypochlorite
    • 10% Hydrogen Peroxide
    • Quaternary Ammonium Compounds (QACs)
  2. Use ATCC microbial strains:
    • Staphylococcus aureus (ATCC 6538)
    • Escherichia coli (ATCC 8739)
    • Pseudomonas aeruginosa (ATCC 9027)
    • Bacillus subtilis spores (ATCC 6633)
    • Candida albicans (ATCC 10231)

5.2 Carrier Preparation for Surface Test

  1. Use stainless steel or glass coupons (1 in²) as carriers.
  2. Sterilize by autoclaving or dry heat.
  3. Inoculate each carrier with 10 µL of microbial suspension (~106 CFU).
  4. Dry carriers under laminar airflow for 30–45 minutes.
  5. Document preparation in Annexure-1: Carrier Inoculation Log.

5.3 Application of Disinfectant

  1. Expose carriers to disinfectant via spray or immersion for specified contact times (e.g., 5, 10, and 15 minutes).
  2. Neutralize residual disinfectant by immersing carriers in validated neutralizing broth (e.g., Dey-Engley broth).
  3. Incubate broth at:
    • 30–35°C for bacteria
    • 20–25°C for fungi
  4. Document in Annexure-2: Disinfectant Exposure Record.
See also  Analytical Method Development: SOP for Qualification of HPLC Columns - V 2.0

5.4 Enumeration and Recovery

  1. After incubation, observe for microbial growth.
  2. Perform serial dilution plating if required for colony counting.
  3. Calculate microbial log reduction:

    Log Reduction = log10(Initial CFU) − log10(Remaining CFU)
  4. Document findings in Annexure-3: Recovery and Reduction Data Sheet.

5.5 Acceptance Criteria

  1. Minimum acceptable log reductions:
    • Bacteria: ≥ 3-log reduction
    • Fungi and spores: ≥ 2-log reduction
  2. No growth should be observed in negative controls.
  3. Positive control (untreated carriers) must confirm initial viable count.

5.6 Reporting

  1. Summarize disinfectant, organism, contact time, and log reduction in tabular format.
  2. Attach validation protocol, raw data, and interpretation sheet.
  3. Prepare final report in Annexure-4: Disinfectant Effectiveness Summary Report.

6. Abbreviations

  • CFU: Colony Forming Units
  • QAC: Quaternary Ammonium Compound
  • IPA: Isopropyl Alcohol
  • SOP: Standard Operating Procedure

7. Documents

  1. Carrier Inoculation Log – Annexure-1
  2. Disinfectant Exposure Record – Annexure-2
  3. Recovery and Reduction Data Sheet – Annexure-3
  4. Disinfectant Effectiveness Summary Report – Annexure-4

8. References

  • USP <1072> – Disinfectants and Antiseptics
  • ICH Q10 – Pharmaceutical Quality System
  • WHO GMP Guidelines – Environmental Monitoring

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Carrier Inoculation Log

Date Organism Carrier Type CFU Applied Inoculated By
18/05/2025 E. coli Stainless Steel 1.2 × 106 Rajesh Kumar

Annexure-2: Disinfectant Exposure Record

Carrier ID Disinfectant Contact Time Neutralizer Tested By
DC130-E01 IPA 70% 5 min D/E Broth Sunita Reddy

Annexure-3: Recovery and Reduction Data Sheet

Organism Initial CFU Recovered CFU Log Reduction Status
E. coli 1.0 × 106 8.0 × 102 3.10 Pass

Annexure-4: Disinfectant Effectiveness Summary Report

70% IPA and QAC-based disinfectants demonstrated ≥ 3-log reduction against Gram-positive and Gram-negative bacteria. Fungal log reduction for C. albicans was ≥ 2.2. All disinfectants passed acceptance criteria for defined contact times.

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Expanded to include fungal log reduction and neutralization protocol Annual Review
See also  Analytical Method Development: Antimicrobial Effectiveness Method Development - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Cleaning of Solution Preparation Vessels – V 2.0
Next Post: API Manufacturing: SOP for Approval of Analytical Methods and Specifications – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version